Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Most Biosimilars Would Need Clinical Trials, ASCO Tells House Panel

Executive Summary

While urging Congress to write legislation that allows FDA to decide which scientific data are needed to approve follow-on biologics, comments from the American Society of Clinical Oncology to a House subcommittee note that clinical trials will be necessary for most FOBs

You may also be interested in...



Biologics Safety: Stronger Pharmacovigilance For First-In-Class BLAs Urged In JAMA Report

Over 23 percent of biologics were subject to post-approval “Dear Doctor” communications or black box warnings during a 12-year period, study finds.

FDA Gains Insight For Biosimilars From Brand Manufacturing Changes

FDA has identified a variety of scientific studies that would be needed to support approval of follow-on biologics based on the agency's experience in reviewing applications for biologics manufacturing changes

Draft WHO Guidance Provides Two Pathways For Biosimilars

Clinical trials would be required for most biosimilars under two approval scenarios that are being developed by the World Health Organization

Related Content

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel